Showing results (1-10 of 98) with videos related to
Sort By:
Pageof 10
European Journal of Pharmacology|January 3, 2007
Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortexWeldon E Horner, David E Johnson, Anne W Schmidt, et al.European Journal of Pharmacology|January 4, 2005
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine releaseDavid E Johnson, Frank M Nedza, Douglas K Spracklin, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposuresKarthik Venkatakrishnan, Elaine Tseng, Frederick R Nelson, et al.Diabetes|April 28, 2005
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemiaDavid E Johnson, Hanae Yamazaki, Karen M Ward, et al.Biochemical Pharmacology|June 9, 2009
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognitionHans Rollema, Mihály Hajós, Patricia A Seymour, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 13, 2006
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effectsKaren L Houseknecht, Alan S Robertson, William Zavadoski, et al.Expert Review of Respiratory Medicine|June 8, 2010
Varenicline in smoking cessationSerena Tonstad, Hans RollemaPsychopharmacology|July 8, 2018
The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature dataHans Rollema, Raymond S HurstPharmacology & Therapeutics|August 29, 2012
Nicotinic acetylcholine receptors: from basic science to therapeuticsRaymond Hurst, Hans Rollema, Daniel BertrandClinical Therapeutics|August 30, 2021
A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral VareniclineJeffrey Nau, David J Wyatt, Hans Rollema, et al.Pageof 10